Search research articles
Contact Us
Filters
Showing results (21-30 of 642) with videos related to
Page
of 65
Sort By:
Expert Review of Anticancer Therapy
|
August 22, 2020
Development of chemotherapeutics for unresectable advanced esophageal cancer
Hiroshi Imazeki, Ken Kato
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
April 3, 2015
[Strategies to minimize toxicities during chemoradiotherapy for esophageal cancer]
Sayako Yuda, Ken Kato
Healthcare Management Forum
|
September 21, 2017
Japanese healthcare: Fostering competition and controlling costs
James H Tiessen, Ken Kato
Military Medicine
|
September 7, 2007
Relationships between the eligibility process, trust in the U.S. health care system, and patient satisfaction with the Houston Veterans Affairs Medical Center
Ken Kato, Kimberly J O'Malley
Gastroenterology
|
February 12, 2022
Reply
Ken Kato, Tomohiro Kadota, Seiichiro Abe
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
October 22, 2019
[Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future]
Hiroshi Imazeki, Ken Kato, Narikazu Boku
Expert Opinion on Biological Therapy
|
October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
Kentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research
|
May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
Yuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)
|
April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma
Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety
|
April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Page
of 65
Search research articles
Search
Showing results (21-30 of 642) with videos related to
Sort By:
Page
of 65
Expert Review of Anticancer Therapy
|
August 22, 2020
Development of chemotherapeutics for unresectable advanced esophageal cancer
Hiroshi Imazeki, Ken Kato
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
April 3, 2015
[Strategies to minimize toxicities during chemoradiotherapy for esophageal cancer]
Sayako Yuda, Ken Kato
Healthcare Management Forum
|
September 21, 2017
Japanese healthcare: Fostering competition and controlling costs
James H Tiessen, Ken Kato
Military Medicine
|
September 7, 2007
Relationships between the eligibility process, trust in the U.S. health care system, and patient satisfaction with the Houston Veterans Affairs Medical Center
Ken Kato, Kimberly J O'Malley
Gastroenterology
|
February 12, 2022
Reply
Ken Kato, Tomohiro Kadota, Seiichiro Abe
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
October 22, 2019
[Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future]
Hiroshi Imazeki, Ken Kato, Narikazu Boku
Expert Opinion on Biological Therapy
|
October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
Kentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research
|
May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data
Yuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)
|
April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma
Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety
|
April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Page
of 65